Overview of Myeloproliferative Disorders
February 25, 2017
In this interview we discuss clinical developments in essential thrombocythemia, polycythemia vera, and myelofibrosis, as well as the latest treatment options.
Srdan Verstovsek, MD, PhD
Myeloproliferative Neoplasms
June 1, 2016
Myeloproliferative neoplasms are a group of clonal myeloid cell–derived disorders characterized by myeloproliferation without dysplasia, bone marrow hypercellularity, and predisposition to thrombosis, hemorrhage, and bone marrow fibrosis.
Ruxolitinib for Myelofibrosis: From ‘Palliation’ to Prolongation of Survival
July 15, 2013
By inhibiting inflammatory cytokines and controlling the signs and symptoms of myelofibrosis, the patient’s body condition improves as the disease is kept under good control. Ultimately, prolonged exposure of a patient with myelofibrosis to ruxolitinib at a clinically effective dose results in prolongation of the his or her life.
